BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, Hadji P, Halbout P, Harvey NC, Hiligsmann M, Javaid MK, Kanis JA, Kaufman JM, Lamy O, Matijevic R, Perez AD, Radermecker RP, Rosa MM, Thomas T, Thomasius F, Vlaskovska M, Rizzoli R, Cooper C. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 2022;34:695-714. [PMID: 35332506 DOI: 10.1007/s40520-022-02100-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Dimai HP, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Fahrleitner-pammer A, Pietschmann P, Muschitz C, Mccloskey EV, Kanis JA. Osteoporosis treatment in Austria—assessment of FRAX-based intervention thresholds for high and very high fracture risk. Arch Osteoporos 2022;17:141. [DOI: 10.1007/s11657-022-01175-w] [Reference Citation Analysis]
2 Miedany YE, Gadallah NA, Toth M, Hassan W, Elgaafary M, Hassan M, Eissa M, Saber S, Elwakil W, Mahran S. Osteoporosis clinical practice guideline: romosozumab for treating severe osteoporosis – an update by the Egyptian Academy of Bone Health. Egypt Rheumatol Rehabil 2022;49:52. [DOI: 10.1186/s43166-022-00150-0] [Reference Citation Analysis]
3 El Miedany Y, Gadallah NA, Toth M. Optimizing osteoporosis management: targeting to treat — an initiative by the Egyptian Academy of Bone Health. Egypt Rheumatol Rehabil 2022;49:61. [DOI: 10.1186/s43166-022-00161-x] [Reference Citation Analysis]
4 Geusens P, Appelman-dijkstra N, Lems W, van den Bergh J. Romosozumab for the treatment of postmenopausal women at high risk of fracture. Expert Opinion on Biological Therapy 2022. [DOI: 10.1080/14712598.2022.2152320] [Reference Citation Analysis]
5 Messina OD, Vidal M, Torres JAM, Vidal LF, Arguissain C, Pereira RM, Clark P, Cerdas Perez S, Campusano C, Lazaretti-castro M, Zerbini C, Scali JJ, Mendez Sanchez L, Peralta-pedrero ML, Cavallo A, Valdivia Ibarra FJ, Hernandez Pérez T. Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update. Aging Clin Exp Res 2022. [DOI: 10.1007/s40520-022-02261-2] [Reference Citation Analysis]
6 Kanis JA, Mccloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-hughes B, Maggi S, Reginster J. Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clin Exp Res 2022. [DOI: 10.1007/s40520-022-02216-7] [Reference Citation Analysis]
7 Fuggle N, Al-daghri N, Bock O, Branco J, Bruyère O, Casado E, Cavalier E, Cortet B, de Wit M, Giusti A, Halbout P, Harvey NC, Hiligsmann M, Kaufman J, Kurth A, Maggi S, Matijevic R, Minisola S, Palacios S, Radermecker RP, Thomasius F, Tuzun S, Veronese N, Kanis JA, Reginster J, Rizzoli R, Cooper C. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res 2022. [DOI: 10.1007/s40520-022-02272-z] [Reference Citation Analysis]
8 Kanis JA, Mccloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-hughes B, Maggi S, Reginster J. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int 2022. [DOI: 10.1007/s00198-022-06567-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Geusens P, Appelman-Dijkstra NM, Zillikens C, Willems H, Lems WF, van den Bergh J. How to implement guidelines and models of care. Best Pract Res Clin Rheumatol 2022;:101759. [PMID: 35729036 DOI: 10.1016/j.berh.2022.101759] [Reference Citation Analysis]
10 Curtis EM, Dennison EM, Cooper C, Harvey NC. Osteoporosis in 2022: Care gaps to screening and personalised medicine. Best Pract Res Clin Rheumatol 2022;:101754. [PMID: 35691824 DOI: 10.1016/j.berh.2022.101754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ip TP. Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk. Journal of Clinical Rheumatology and Immunology 2022;22:10-9. [DOI: 10.1142/s266134172230004x] [Reference Citation Analysis]
12 Mcclung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgraduate Medicine. [DOI: 10.1080/00325481.2022.2069582] [Reference Citation Analysis]